Evogene
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
AI and Digital Health
Evogene Ltd. (Nasdaq/TASE: EVGN) is focused on improving the probability of success in small-molecule drug discovery. Through ChemPass AI™ (developed in collaboration with Google Cloud), our proprietary generative platform, we design novel, multi-parameter optimized molecules that meet key development criteria, including potency, selectivity, PK/PD, and safety from the earliest stages of discovery. By combining ultra large-scale chemical space exploration with iterative computational-experimental validation, ChemPass AI™ enables the generation of differentiated, patentable chemotypes aligned with defined target product profiles. We partner with pharma and biotech companies to translate validated biology into development-ready chemical assets.
Company HQ City:
Rehovot
Company HQ State:
N/A
Company HQ Country:
Israel
Year Founded:
2002
Lead Product in Development:
Evogene operates a platform-driven model. Its core offering is the ChemPass AI™ platform, a proprietary generative discovery engine for novel small-molecule design. ChemPass enables the generation of novel, multi-parameter optimized molecules aligned with defined target product profiles, integrating large-scale chemical space exploration with iterative computational–experimental (DMTA) validation to deliver development-ready candidates. In addition, Evogene advances an internal pipeline and co-development assets with multiple partners . Through its fully owned subsidiary, AgPlenus, which applies the same computational platform, we promote innovative agrochemical products. This dual application demonstrates the robustness and scalability of the platform across industries, supporting both drug discovery and agricultural product development.
CEO
Ofer Haviv
Development Phase of Lead Product
Discovery
Exchange
Nasdaq
Ticker
EVGN
When you expect your next catalyst update?
Due to the nature of these milestones, it is difficult for the company to provide precise timing estimates for when these events will occur, even on a quarterly basis. Nevertheless, we estimate that the first milestone is likely to take place during 2027, while the second milestone is expected to occur in 2028.
What is your next catalyst (value inflection) update?
We are seeing two key milestones in Evogene’s success in the coming years:
1. Signing a drug development agreement with a large pharmaceutical or biotech company. We expect such an agreement would finance Evogene’s operations and include milestone-based payments as well as royalties.
2. Advancement of the company’s drug development collaborations to the stage of entry into clinical trials. This milestone could also be achieved through the company’s internal development programs.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}